Add to a list

Inactive Instrument

Level Brands Inc Stock NYSE

US52730Q2093

Last Transcript: Level Brands Inc

CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

08-13

More transcripts

Analysts' recommendations: Level Brands Inc

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
23-10-05	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
21-06-18	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Press Releases: Level Brands Inc

09-24	Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation	PR
09-02	CbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness	PR
08-13	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
08-10	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
08-03	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR

More press releases

Managers and Directors: Level Brands Inc

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	2023-02-28
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	2018-12-31
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	2017-02-28
William Raines BRD	Director/Board Member	66	2019-04-18
Scott Stephen CHM	Chairman	60	2022-06-02

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	5.19M 4.57M 4.32M 3.92M 7.36M 499M 7.4M 51.72M 19.97M 254M 19.5M 19.08M 817M	P/E 2026 *	-1.4x	P/E 2027 *	-2.44x
Enterprise Value	5.19M 4.57M 4.32M 3.92M 7.36M 499M 7.4M 51.72M 19.97M 254M 19.5M 19.08M 817M	EV / Sales 2026 *	0.24x	EV / Sales 2027 *	0.18x
Free-Float	90%	Yield 2026 *	-	Yield 2027 *	-

09-02	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI
08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
08-13	CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026
08-13	CbdMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
07-14	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	CI
07-14	CbdMD Expands Oasis Beverage Distribution to South Carolina	MT
07-07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
06-16	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
05-14	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
05-14	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
05-14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LEVEL BRANDS INC	-0.51%	+9.23%	-	-	5.24M
ELI LILLY AND COMPANY	+0.11%	+2.76%	+63.52%	+115.51%	1,055B
JOHNSON & JOHNSON	+0.27%	+0.73%	+51.33%	+73.10%	654B
ABBVIE INC.	+0.73%	+0.88%	+20.70%	+73.89%	467B
ROCHE HOLDING AG	-1.36%	-0.39%	+40.20%	+41.03%	348B
NOVARTIS AG	+1.34%	+5.47%	+23.37%	+31.30%	275B
ASTRAZENECA PLC	-0.48%	-0.06%	+13.56%	+12.36%	258B
AMGEN INC.	+0.85%	+8.42%	+53.17%	+55.45%	224B
GILEAD SCIENCES, INC.	+0.85%	+1.40%	+35.78%	+101.47%	187B
NOVO NORDISK A/S	-0.30%	-10.41%	-27.62%	-61.04%	171B
Average	+0.06%	+0.74%	+30.45%	+49.23%	404.26B
Weighted average by Cap.	-0.05%	+1.32%	+40.69%	+69.05%

	2026 *	2027 *
Net sales	21.92M 19.28M 18.23M 16.54M 31.06M 2.1B 31.24M 218M 84.31M 1.07B 82.31M 80.53M 3.45B	28.6M 25.15M 23.78M 21.57M 40.51M 2.74B 40.75M 285M 110M 1.4B 107M 105M 4.5B
Net income	-3.33M -2.93M -2.77M -2.51M -4.72M -320M -4.75M -33.18M -12.81M -163M -12.51M -12.24M -524M	-4.95M -4.35M -4.11M -3.73M -7.01M -475M -7.05M -49.25M -19.02M -242M -18.57M -18.17M -779M
Net Debt	-	-

Level Brands Inc Stock NYSE

Stocks

US52730Q2093

Pharmaceuticals

Valuation: Level Brands Inc

Latest news: Level Brands Inc

Last Transcript: Level Brands Inc

Analysts' recommendations: Level Brands Inc

Press Releases: Level Brands Inc

Quotes and Performance

Managers and Directors: Level Brands Inc

Other Pharmaceuticals

Financials

Company Profile